Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.775
Bid: 9.75
Ask: 9.80
Change: 0.00 (0.00%)
Spread: 0.05 (0.513%)
Open: 9.55
High: 0.00
Low: 0.00
Prev. Close: 9.775
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)

12 Dec 2018 13:01

Edison Investment Research Limited Edison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX) 12-Dec-2018 / 13:01 GMT/BST


London, UK, 12 December 2018

Edison issues outlook on e-Therapeutics (ETX)

e-Therapeutics (ETX) has announced a long-awaited research collaboration with Novo Nordisk (Novo) on early target discovery in diabetes. This is the first commercial collaboration in ETX's history and will last for at least a year. The financial terms of the transaction were not disclosed but the deal should be recognised for its validation of ETX's disease-aware network-driven drug discovery (NDD) platform. This is expected to be the first in an expected series of deals on the NDD platform and the assets generated from it.

We have maintained our previous valuation at £63.5m or 24p per share and will review the impact of the transaction on ETX's cash position at the FY19 results. We continue to expect more than one such transaction although the timing is uncertain.Click here to view the full report.

All reports published by Edison are available to download free of charge from its websitewww.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Andy Smith, +44 (0)20 3077 5700healthcare@edisongroup.comLearn more at www.edisongroup.com and connect with Edison on:LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_ResYouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

757183 12-Dec-2018 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
4th Sep 20084:35 pmRNSDirectorate Change
21st Jul 20083:42 pmRNSFinal Results
6th May 20087:03 amRNSLaunch of Consultancy Service
4th Apr 20082:38 pmRNSDirector/PDMR Shareholding
5th Feb 200812:02 pmRNSHolding(s) in Company
22nd Jan 20087:01 amRNSETS2101 preclinical progress
10th Dec 200711:18 amRNSPreclinical Update
3rd Dec 20074:58 pmRNSDirector/PDMR Shareholding
28th Nov 20078:00 amRNSFirst day of dealings on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.